Les inconvénients sociaux associés à la myasthénie grave et à son traitement: une étude multicentrique transversale.

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Avatar du membre

Auteur du sujet
Messages : 5291
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 10 Firefox
Genre :
Zodiaque :
Âge : 61
Contact :

Les inconvénients sociaux associés à la myasthénie grave et à son traitement: une étude multicentrique transversale.

Message par Pboulanger » 07 mars 2017 11:58


Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28235967

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
Nagane Y1, Murai H2, Imai T3, Yamamoto D3, Tsuda E3, Minami N4, Suzuki Y5, Kanai T6, Uzawa A6, Kawaguchi N7, Masuda M8, Konno S9, Suzuki H10, Aoki M11, Utsugisawa K1.
BMJ Open. 2017 Feb 23;7(2):e013278. doi: 10.1136/bmjopen-2016-013278.


    To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations with its disease and treatment.
    Cross-sectional study.
    We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration.
    All patients completed a questionnaire on social disadvantages resulting from MG and its treatment and a 15-item MG-specific quality of life scale at study entry. Clinical severity at the worst condition was graded according to the MG Foundation of America classification, and that at the current condition was determined according to the quantitative MG score and MG composite. Maximum dose and duration of dose ≥20 mg/day of oral prednisolone during the disease course were obtained from the patients' medical records. Achievement of the treatment target (minimal manifestation status with prednisolone at ≤5 mg/day) was determined at 1, 2 and 4 years after starting treatment and at study entry.
    We found that 27.2% of the patients had experienced unemployment, 4.1% had been unwillingly transferred and 35.9% had experienced a decrease in income, 47.1% of whom reported that the decrease was ≥50% of their previous total income. In addition, 49.0% of the patients reported feeling reduced social positivity. Factors promoting social disadvantages were severity of illness, dose and duration of prednisolone, long-term treatment, and a depressive state and change in appearance after treatment with oral steroids. Early achievement of the treatment target was a major inhibiting factor.
    Patients with MG often experience unemployment, unwilling job transfers and a decrease in income. In addition, many patients report feeling reduced social positivity. To inhibit the social disadvantages associated with MG and its treatment, greater focus needs to be placed on helping patients with MG resume a normal lifestyle as soon as possible by achieving the treatment target.


Retourner vers « Informations »